Celcuity announced FDA approval for the REVTORPYK targeted therapy to treat HR+/HER2- breast cancer without a PIK3CA mutation. The drug reduced the risk of disease progression or death by up to 76% in clinical trials.
Celcuity announced FDA approval for the REVTORPYK targeted therapy to treat HR+/HER2- breast cancer without a PIK3CA mutation. The drug reduced the risk of disease progression or death by up to 76% in clinical trials.